BY
BYSI.O
—
NASDAQ
Biotechnology & Medical Research
Beyondspring Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
48,1M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
3,1 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
18
Day range
$1,46–$1,60
Prev close
$1,54
Open
$1,56
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Beyondspring Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, primarily in the field of immuno-oncology.
Business. Beyondspring Inc (BYSI.O) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
3,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to BYSI.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Beyondspring Inc (BYSI.O) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDBeyondspring Inc operates with a negative equity position of $32.16 million and a cash and equivalents balance of $7.79 million, indicating a liquidity position that is constrained by its negative net worth. The company's market capitalization of $60.45 million is supported by a market price of $1.47 per share, with no dilution risk currently identified. The enterprise value to EBITDA ratio of -5.89 reflects the company's current unprofitable status and the challenges it faces in generating positive cash flows.
The company's return on equity of 3.13% is modest, while its return on assets of -3.88% indicates that it is not effectively utilizing its assets to generate profit. These metrics are below the typical thresholds for a profitable biotechnology firm, suggesting that Beyondspring is in an early or development phase with limited revenue generation.
Beyondspring's revenue is currently reported at $0, and its operating income is negative at $8.95 million, indicating that the company is not yet generating revenue from its operations and is incurring significant operating losses. The company's net income is also negative at $1.01 million, further emphasizing its unprofitable status.
The company's capital expenditure of $50,000 is minimal, suggesting that it is not investing heavily in new projects or infrastructure at this time. The outlook for the current fiscal year indicates a continuation of the current trend, with no significant changes in revenue or expenses expected. The next fiscal year is also projected to maintain the current trajectory, with no substantial growth anticipated.
The risk assessment for Beyondspring indicates a low liquidity risk, as the company has no immediate filing-based liquidity or dilution flags. However, the company's negative equity and operating cash flow of -$19.77 million suggest that it may face liquidity challenges in the future. The dilution risk is also assessed as low, with no immediate pressure for share issuance.
Recent events, including the latest actual EPS of -$0.85 and revenue of $1.35 million, reflect the company's ongoing financial challenges. The ESG scores indicate a strong governance pillar with a score of 82.27, but a low social pillar score of 24.90 and a high ESG controversies score of 100.00, suggesting potential reputational risks.
Key takeaways
- Beyondspring Inc is a clinical-stage biopharmaceutical company with no current revenue and significant operating losses.
- The company's financial position is characterized by negative equity and a constrained liquidity position.
- The company's return on equity is modest, while its return on assets is negative, indicating inefficiency in asset utilization.
- The company's capital expenditure is minimal, and the outlook for the next fiscal year does not indicate significant changes.
- The risk assessment indicates low liquidity and dilution risks, but the company's negative operating cash flow suggests potential future liquidity challenges.
- The ESG scores highlight a strong governance pillar but a weak social pillar and high controversies score.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,17
Market cap
$60.4M
Enterprise valueⓘ
$52.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$32.2M
Net cashⓘ
$7.8M
Current ratioⓘ
1.5
Debt / equityⓘ
0.0
ROAⓘ
-3.9%
ROEⓘ
3.1%
Cash conversionⓘ
1965.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 2 types · extracted from filings & disclosures
Partners1
Bristol-myers Squibb CoBMY.OPartner85%Source ↗
Supply chain
Vendors → BYSI ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE3,1 %Above P75
D/E0,00Above median
Cash Conv19,65Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 136 267 sh7 grants7 insiders
- Director · Stock Options (right to buy) → Ordinary SharesAcquired 18 689 @ $1,64grant · 2026-04-01
- Director · Stock Options (right to buy) → Ordinary SharesAcquired 23 902 @ $1,64grant · 2026-04-01
- Director · Stock Options (right to buy) → Ordinary SharesAcquired 22 165 @ $1,64grant · 2026-04-01
- Director · Stock Options (right to buy) → Ordinary SharesAcquired 20 427 @ $1,64grant · 2026-04-01
- Director · Stock Options (right to buy) → Ordinary SharesAcquired 21 730 @ $1,64grant · 2026-04-01
- Chief Scientific Officer · Stock Options (right to buy) → Ordinary SharesAcquired 17 840 @ $1,64grant · 2026-04-01
- Director, Chief Executive Officer, 10% owner · Stock Options (right to buy) → Ordinary SharesAcquired 11 514 @ $1,80grant · 2026-04-01
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
Source documents
- Beyondspring Inc Market data — financials · 2026-05-27
- Beyondspring Inc Market data — analyst estimates · 2026-05-27
- Beyondspring Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 47 sellsnet -$821K2 insiders · last 365d
- Director, Chief Executive Officer, 10% owner · Ordinary SharesOther 260 582 · 2026-03-20
- 10% owner · Ordinary SharesSold 45 513 @ $1,76$80K · 2025-10-17
- 10% owner · Ordinary SharesSold 85 798 @ $1,72$148K · 2025-10-16
- 10% owner · Ordinary SharesSold 17 960 @ $1,65$30K · 2025-10-15
- 10% owner · Ordinary SharesSold 28 495 @ $1,65$47K · 2025-10-14
- 10% owner · Ordinary SharesSold 107 361 @ $1,70$183K · 2025-10-13
- 10% owner · Ordinary SharesSold 2 390 @ $1,77$4K · 2025-10-10
- 10% owner · Ordinary SharesSold 3 979 @ $1,81$7K · 2025-10-09
- 10% owner · Ordinary SharesSold 7 507 @ $1,77$13K · 2025-10-08
- 10% owner · Ordinary SharesSold 2 100 @ $1,79$4K · 2025-10-07
- 10% owner · Ordinary SharesSold 17 500 @ $1,78$31K · 2025-10-06
- 10% owner · Ordinary SharesSold 600 @ $1,76$1K · 2025-10-03
- 10% owner · Ordinary SharesSold 600 @ $1,73$1K · 2025-10-02
- 10% owner · Ordinary SharesSold 2 601 @ $1,80$5K · 2025-10-01
- 10% owner · Ordinary SharesSold 4 464 @ $1,81$8K · 2025-09-30
- 10% owner · Ordinary SharesSold 500 @ $1,75$875 · 2025-09-29
- 10% owner · Ordinary SharesSold 600 @ $1,68$1K · 2025-09-26
- 10% owner · Ordinary SharesSold 700 @ $1,66$1K · 2025-09-25
- 10% owner · Ordinary SharesSold 2 256 @ $1,68$4K · 2025-09-24
- 10% owner · Ordinary SharesSold 4 106 @ $1,72$7K · 2025-09-23
- 10% owner · Ordinary SharesSold 5 410 @ $1,83$10K · 2025-09-22
- 10% owner · Ordinary SharesSold 3 656 @ $1,79$7K · 2025-09-19
- 10% owner · Ordinary SharesSold 5 307 @ $1,74$9K · 2025-09-18
- 10% owner · Ordinary SharesSold 2 304 @ $1,83$4K · 2025-09-17
- 10% owner · Ordinary SharesSold 840 @ $1,88$2K · 2025-09-16
Short positioning
2.2Mshares short+0.4% vs prior
62.3days to cover
62.1%short of daily vol
428fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
BYSI.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSuppliersPartners
Evidence & claims
From filings & derived data- Return on assets (FY 2025-12-31): -3.9%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 2.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -24.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 2.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 66.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -2.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -20.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 91.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 92.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 166.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -77.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.55xDerived (calculated)
- Current ratio (FY 2025-12-31): 1.54xDerived (calculated)
- Return on equity (FY 2025-12-31): 3.1%Derived (calculated)
- Net income (annual): USD -1.01MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Current assets (annual): USD 20.88MSEC XBRL filing
- Operating cash flow (annual): USD -19.77MSEC XBRL filing
- Shares outstanding (annual): 41.12MSEC XBRL filing
- Current liabilities (annual): USD 13.58MSEC XBRL filing
- Shareholders' equity (annual): USD -32.16MSEC XBRL filing
- Operating income (annual): USD -8.95MSEC XBRL filing
- Cash & equivalents (annual): USD 7.79MSEC XBRL filing
- Capex (annual): USD 50KSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-04-01 00:00 UTCINSIDER7 insider transactions — 2026-04 7 derivative
2026-04-01INSIDERMajeti Jiangwen acquired 21.7k sh Stock Options (right to buy) — Director
2026-04-01INSIDERLu Yingjuan June acquired 17.8k sh Stock Options (right to buy) — Chief Scientific Officer
2026-04-01INSIDERHuang Lan acquired 11.5k sh Stock Options (right to buy) — Director, Chief Executive Officer, 10% owner
2026-04-01INSIDERXu Sihai acquired 18.7k sh Stock Options (right to buy) — Director
2026-04-01INSIDERFabbio Patrick acquired 22.2k sh Stock Options (right to buy) — Director
2026-04-01INSIDERKirkby Matthew acquired 23.9k sh Stock Options (right to buy) — Director
2026-04-01INSIDERDelaney Brendan acquired 20.4k sh Stock Options (right to buy) — Director
2026-03-20 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-20INSIDERHuang Lan transacted 260.6k sh Ordinary Shares — Director, Chief Executive Officer, 10% owner
2025-10-17 00:00 UTCINSIDER13 insider transactions — 2025-10 · net sell $553k
2025-10-17INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 45.5k sh Ordinary Shares — 10% owner ~$80k
2025-10-16INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 85.8k sh Ordinary Shares — 10% owner ~$148k
2025-10-15INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 18.0k sh Ordinary Shares — 10% owner ~$30k
2025-10-14INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 28.5k sh Ordinary Shares — 10% owner ~$47k
2025-10-13INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 107.4k sh Ordinary Shares — 10% owner ~$183k
2025-10-10INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 2.4k sh Ordinary Shares — 10% owner ~$4k
2025-10-09INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 4.0k sh Ordinary Shares — 10% owner ~$7k
2025-10-08INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 7.5k sh Ordinary Shares — 10% owner ~$13k
2025-10-07INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 2.1k sh Ordinary Shares — 10% owner ~$4k
2025-10-06INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 17.5k sh Ordinary Shares — 10% owner ~$31k
2025-10-03INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 600 sh Ordinary Shares — 10% owner ~$1k
2025-10-02INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 600 sh Ordinary Shares — 10% owner ~$1k
2025-10-01INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 2.6k sh Ordinary Shares — 10% owner ~$5k
2025-09-30 00:00 UTCINSIDER21 insider transactions — 2025-09 · net sell $125k
2025-09-30INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 4.5k sh Ordinary Shares — 10% owner ~$8k
2025-09-29INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 500 sh Ordinary Shares — 10% owner ~$1k
2025-09-26INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 600 sh Ordinary Shares — 10% owner ~$1k
2025-09-25INSIDERDecheng Capital China Life Sciences USD Fund III, L.P. sold 700 sh Ordinary Shares — 10% owner ~$1k
Showing the 40 most recent of 52 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage